Endogenous Retroviruses in Acute Myeloid Leukemia

NCT04406207 | Withdrawn

• 1 other identifier: 69HCL19_0851
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for numerous malignant hematologic diseases. Despite recent advances in the field, relapse rates are still high and the first cause of death. The identification of new relevant therapeutic targets is therefore urgently needed. Human endogenous retroviruses (HERVs) are accounting for 8% of the human genome. While silenced at the steady state (mainly by methylation mechanisms), HERVs reactivations have been described in different conditions such as auto-immune diseases or cancer, leading to an innate and adaptive immune response. Several questions are raised in the field of hematology where few data are available, and the exact role of HERVs in these diseases is still to define. Our team is currently working on the role of HERVs in different types of cancer. We developed a bioinformatics approach to identify overexpressed HERVs from RNAseq data. We also developed in vitro assays to assess the immunogenicity of different peptides from HERVs open reading frames and showed that several epitopes shared among different HERVs can induce a specific CD8+ T cell response. More recently, we have analyzed 151 acute myeloid leukemia (AML) RNAseq data from TCGA and identified multiple overexpressed HERVs in this disease. Immunogenicity test are currently ongoing with patient's blood at diagnosis. The main objective of this part of our project is to analyze the establishment of a HERVs-specific CD8+ T cell response participating in graft-versus-leukemia effect after HSCT for AML patients. Secondary objectives are to analyze relations between this response and different clinical factors such as the onset of GVHD or relapse. Peripheral blood mononuclear cells (PBMCs) from AML patients will be extracted and frozen at different time point: diagnosis, complete remission (pre-HSCT) and after HSCT (M3, M6 and M12). This prospective protocol is currently ongoing at the Centre Hospitalier Lyon Sud, with around 30 samples already available. After having selected relevant HERVs, specific dextramers identified by DNA barcode will be synthesized. These dextramers allowing the identification of specific T cell responses directed against up to 1000 epitopes, we will be able to screen specific T cells directed against HERVs overexpressed in AML for most common HLA. Dextramer staining will be performed on PBMCs after thawing. Positive cells will be sorted by flow cytometry and DNA will be expanded by PCR before performing sequencing, allowing the identification of specific sequences by its unique DNA barcode. The analyze of HERVs-specific CD8+ T cell responses after HSCT will allow us to better define HERVs role in the onset of graft-versus-leukemia effect. A specific T cell response without GvHD will define the relevance of such peptides as tumor specific antigens.

Conditions

Leukemia, Myeloid

Outcome Measures

Primary Outcomes (8)

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  Day 0

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  At remission <- Day 0 + 1 month

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  Before transplant <- Day 0 + 3 month

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  1 month

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  3 months

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  6 months

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  12 months

• HERVs-specific CD8+ T cells responses

  HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.

  At relapse: up to 6 month after day 0

Study Arms (1)

Patients

Patients relapsing or not after hematopoietic stem cell transplantation.

Other: Demonstration of T cell responses

Interventions

Demonstration of T cell responses OTHER

Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients. The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest.

Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults \>= 18 years old with acute myeloid leukemia

You may qualify if:

• Acute myeloid leukemia (all subtypes)
• Stem cell transplantation indication
• Non opposition to the study

You may not qualify if:

• \- Intensive care unit at diagnosis

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

MeSH Terms

Conditions

Leukemia, Myeloid

Condition Hierarchy (Ancestors)

Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Vincent ALCAZER, MD

  Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 13, 2020
• First Posted: May 28, 2020
• Study Start: June 1, 2020
• Primary Completion: January 6, 2022
• Study Completion: January 6, 2022
• Last Updated: August 22, 2022

Record last verified: 2022-08